Literature DB >> 30082821

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Stephen E Kurtz1, Christopher A Eide1,2, Andy Kaempf3, Motomi Mori3,4, Cristina E Tognon1,2, Uma Borate1, Brian J Druker1,2, Jeffrey W Tyner5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30082821      PMCID： PMC6168939          DOI： 10.1038/s41375-018-0225-7

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  Acute Myeloid Leukemia.

Authors:  Hartmut Döhner; Daniel J Weisdorf; Clara D Bloomfield
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

2.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia.

Authors:  Stefan P Glaser; Erinna F Lee; Evelyn Trounson; Philippe Bouillet; Andrew Wei; W Douglas Fairlie; David J Izon; Johannes Zuber; Amy R Rappaport; Marco J Herold; Warren S Alexander; Scott W Lowe; Lorraine Robb; Andreas Strasser
Journal:  Genes Dev       Date:  2012-01-15       Impact factor: 11.361

3.  JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Authors:  Riikka Karjalainen; Tea Pemovska; Mihaela Popa; Minxia Liu; Komal K Javarappa; Muntasir M Majumder; Bhagwan Yadav; David Tamborero; Jing Tang; Dmitrii Bychkov; Mika Kontro; Alun Parsons; Minna Suvela; Mireia Mayoral Safont; Kimmo Porkka; Tero Aittokallio; Olli Kallioniemi; Emmet McCormack; Bjørn T Gjertsen; Krister Wennerberg; Jonathan Knowles; Caroline A Heckman
Journal:  Blood       Date:  2017-06-15       Impact factor: 22.113

4.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.

Authors:  Meili Zhang; Lesley A Mathews Griner; Wei Ju; Damien Y Duveau; Rajarshi Guha; Michael N Petrus; Bernard Wen; Michiyuki Maeda; Paul Shinn; Marc Ferrer; Kevin D Conlon; Richard N Bamford; John J O'Shea; Craig J Thomas; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-22       Impact factor: 11.205

5.  Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Authors:  Stephen E Kurtz; Christopher A Eide; Andy Kaempf; Vishesh Khanna; Samantha L Savage; Angela Rofelty; Isabel English; Hibery Ho; Ravi Pandya; William J Bolosky; Hoifung Poon; Michael W Deininger; Robert Collins; Ronan T Swords; Justin Watts; Daniel A Pollyea; Bruno C Medeiros; Elie Traer; Cristina E Tognon; Motomi Mori; Brian J Druker; Jeffrey W Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

Review 6.  Programming cancer cells for high expression levels of Mcl1.

Authors:  Franziska Ertel; Mai Nguyen; Anne Roulston; Gordon C Shore
Journal:  EMBO Rep       Date:  2013-03-12       Impact factor: 8.807

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

Authors:  Courtney D DiNardo; Keith W Pratz; Anthony Letai; Brian A Jonas; Andrew H Wei; Michael Thirman; Martha Arellano; Mark G Frattini; Hagop Kantarjian; Relja Popovic; Brenda Chyla; Tu Xu; Martin Dunbar; Suresh K Agarwal; Rod Humerickhouse; Mack Mabry; Jalaja Potluri; Marina Konopleva; Daniel A Pollyea
Journal:  Lancet Oncol       Date:  2018-01-12       Impact factor: 41.316

9.  Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.

Authors:  Bruno C Medeiros; Sacha Satram-Hoang; Deborah Hurst; Khang Q Hoang; Faiyaz Momin; Carolina Reyes
Journal:  Ann Hematol       Date:  2015-03-20       Impact factor: 3.673

10.  Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.

Authors:  Michaela Waibel; Vanessa S Solomon; Deborah A Knight; Rachael A Ralli; Sang-Kyu Kim; Kellie-Marie Banks; Eva Vidacs; Clemence Virely; Keith C S Sia; Lauryn S Bracken; Racquel Collins-Underwood; Christina Drenberg; Laura B Ramsey; Sara C Meyer; Megumi Takiguchi; Ross A Dickins; Ross Levine; Jacques Ghysdael; Mark A Dawson; Richard B Lock; Charles G Mullighan; Ricky W Johnstone
Journal:  Cell Rep       Date:  2013-11-21       Impact factor: 9.423
View more
  6 in total

1.  Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.

Authors:  William G Rice; Stephen B Howell; Hongying Zhang; Nasrin Rastgoo; Andrea Local; Stephen E Kurtz; Pierrette Lo; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Brian J Druker; Jeffrey W Tyner
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

2.  Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Authors:  Heikki Kuusanmäki; Aino-Maija Leppä; Petri Pölönen; Mika Kontro; Olli Dufva; Debashish Deb; Bhagwan Yadav; Oscar Brück; Ashwini Kumar; Hele Everaus; Bjørn T Gjertsen; Merja Heinäniemi; Kimmo Porkka; Satu Mustjoki; Caroline A Heckman
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

3.  Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.

Authors:  Sara J C Gosline; Cristina Tognon; Michael Nestor; Sunil Joshi; Rucha Modak; Alisa Damnernsawad; Camilo Posso; Jamie Moon; Joshua R Hansen; Chelsea Hutchinson-Bunch; James C Pino; Marina A Gritsenko; Karl K Weitz; Elie Traer; Jeffrey Tyner; Brian Druker; Anupriya Agarwal; Paul Piehowski; Jason E McDermott; Karin Rodland
Journal:  Clin Proteomics       Date:  2022-07-27       Impact factor: 5.000

4.  Sample-efficient identification of high-dimensional antibiotic synergy with a normalized diagonal sampling design.

Authors:  Jennifer Brennan; Lalit Jain; Sofia Garman; Ann E Donnelly; Erik Scott Wright; Kevin Jamieson
Journal:  PLoS Comput Biol       Date:  2022-07-18       Impact factor: 4.779

Review 5.  Alterations to DNMT3A in Hematologic Malignancies.

Authors:  Kartika Venugopal; Yang Feng; Daniil Shabashvili; Olga A Guryanova
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 13.312

6.  Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.

Authors:  Shujuan Huang; Chenying Li; Xiang Zhang; Jiajia Pan; Fenglin Li; Yunfei Lv; Jingwen Huang; Qing Ling; Wenle Ye; Shihui Mao; Xin Huang; Jie Jin
Journal:  Mol Oncol       Date:  2020-07-03       Impact factor: 6.603
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.